Clinical trial
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With…
NCT00441090 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00441090 |
|---|---|
| Title | Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
| Official title | A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP). |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic |
| Intervention type | Drug |
| Interventions | Placebo, Avatrombopag tablets |
| Enrollment | 64 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Feb 28, 2007 |
| Last update posted | Mar 7, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: